A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
[HTML][HTML] A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
D Wang, J Wang, G Hu, W Wang, Y Xiao, H Cai… - Blood, 2021 - Elsevier
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
D Wang, J Wang, G Hu, W Wang, Y Xiao, H Cai… - …, 2021 - pubmed.ncbi.nlm.nih.gov
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
[PDF][PDF] A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
BCAR T-cell - blood, 2021 - cn.iasobio.com
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
[PDF][PDF] A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
BCAR T-cell - blood, 2021 - academia.edu
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
D Wang, J Wang, G Hu, W Wang, Y Xiao, H Cai… - Blood, 2021 - europepmc.org
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …